Previously, we introduced a protein nanoparticle-based vaccine candidate, S∆C-Fer, which displays a truncated form of the prefusion SARS-CoV-2 spike-protein ectodomain trimer from the Wuhan-1 isolate on self-assembling Heliobacter pylori ferritin nanoparticles 14. Indeed, candidate ferritin-based nanoparticle vaccines have shown robust humoral immune responses against SARS-CoV-2 14, 15, 16 and other viral glycoproteins 17, 18, 19, 20, 21, including showing safety and efficacy in clinical trials 20, 22. Protein nanoparticle vaccines, compared to isolated protein subunits, are more readily taken up by antigen-presenting dendritic cells 10, 11 and the multivalent presentation of the antigen facilitated by the nanoparticles promotes receptor clustering and subsequent activation of B cells 12, 13. Finally, as SARS-CoV-2 becomes endemic, worldwide immunization of the pediatric population, including of infants, remains an unmet need 9. Fourth, SARS-CoV-2 variants of concern (VOCs) capable of evading natural or vaccine-induced humoral immunity continue to emerge 8. Third, the protection against infection provided by vaccine-induced or infection-induced immunity wanes with time, which has led to frequent booster vaccine doses 7. Second, affordability continues to be an obstacle to global vaccine accessibility, including the cost of low-temperature storage and transport 5, 6. First, as of May, 2022, the WHO estimates that almost one billion people globally remain unvaccinated against SARS-CoV-2 4. Nonetheless, there remains an urgent public health need for vaccine interventions. The COVID-19 pandemic was met with record-breaking vaccine development speed 1, 2, and widespread vaccination is estimated to have prevented over 14 million deaths in the first year of implementation 3. DCFHP-alum has potential as a once-yearly (or less frequent) booster vaccine, and as a primary vaccine for pediatric use including in infants. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. Following a booster ~one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1.

While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs).

Nature Communications volume 14, Article number: 2149 ( 2023) A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

Hexapro vaccine